Johnson & Johnson (JNJ.US) announced in a statement that it intends to split into two companies, dealing separately with the production and sale of care products, including plasters, soaps and shampoos, and the pharmaceutical and medical segment (including vaccines for COVID). The company plans to complete the entire restructuring process within 18 to 24 months. Currently, the market has reacted positively to the news of the demerger, with shares currently up nearly 1.5%.
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appAlex Gorsky, J&J’s chief executive, said that separation is “the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities for our talented global team, drive profitable growth, and — most importantly — improve healthcare outcomes for people around the world”.
The company wants to focus on pharmaceuticals and medical devices, and has decided to spin off an entity focusing on consumer products, most likely through a share offering. The whole transaction is to be tax-free, and the dividend level is to remain unchanged.
The company's shares opened with a large gap and are now breaking out of the consolidation zone (orange box). For the demand side, the key is to maintain the lower limit of the consolidation zone, near the level of $162 per share. A bottom breakout from this level could lead to a deepening of declines to the area of $157. Source: xStation 5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
